Shopping Cart
Remove All
Your shopping cart is currently empty
Pt(IV)-M13 is a platinum (IV) prodrug conjugated with a perfluoroaryl macrocyclic peptide, capable of crossing the blood-brain barrier. It exhibits cytotoxicity towards glioblastoma stem cells and enhances platinum uptake in the brain, making it a valuable tool for glioblastoma research.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 10 mg | Inquiry | Inquiry | Inquiry | |
| 50 mg | Inquiry | Inquiry | Inquiry |
| Description | Pt(IV)-M13 is a platinum (IV) prodrug conjugated with a perfluoroaryl macrocyclic peptide, capable of crossing the blood-brain barrier. It exhibits cytotoxicity towards glioblastoma stem cells and enhances platinum uptake in the brain, making it a valuable tool for glioblastoma research. |
| In vitro | Pt(IV)-M13, at concentrations ranging from 1-30 μM over a duration of 80 hours, exhibits an IC50 of approximately 5 μM against G9 neurospheres, similar to cisplatin. |
| In vivo | Administering a single dose of Pt(IV)-M13 (2.5 mg/kg;I.V.) to mice can significantly enhance platinum accumulation in the brain, achieving levels 15 times higher than those observed with cisplatin. |
| Molecular Weight | 2947.63 |
| Formula | C120H190ClF8N30O28PtS2 |
| Storage | keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.